Stocks fell at German pharmaceutical firm Merck KgaA after the key drug Evobrutinib failed to achieve the targets hoped for by researchers in decisive clinical trials in patients with forms of relapsing multiple sclerosis (RMS). Shares in Merck KgaA were losing more than 14% in early morning trading in Germany. The company said its Evolution RMS 1 and Evolution RMS 2 trials investigating the efficacy and safety of Evobrutinib did not meet its primary endpoint of annualized relapse rate (ARR) for up to 156 weeks compared to oral Teriflunomide in both studies. Of note, Teriflunomide ARR values w…